Cetuximab-induced esophageal ulcer: the first report in literature

Cetuximab, a monoclonal antibody to the extracellular domain of epidermal growth factor receptor (EGFR), is indicated for the treatment of metastatic colorectal cancers and head-neck cancers. Cetuximab is generally well tolerated but some side effects, such as skin rash, malaise, vomiting, diarrhea,...

Full description

Saved in:
Bibliographic Details
Published in:Libyan journal of medicine 2014-01, Vol.9 (1), p.23723
Main Authors: Babacan, Taner, Turkbeyler, Ibrahim Halil, Dag, Muhammet Sait, Dilli, Ismail, Balakan, Ozan, Altundag, Kadri
Format: Article
Language:English
Subjects:
Abdomen, Acute - etiology
Adenocarcinoma - complications
Adenocarcinoma - diagnosis
Adenocarcinoma - genetics
Adenocarcinoma - secondary
Adenocarcinoma - therapy
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biopsy
Camptothecin - administration & dosage
Camptothecin - analogs & derivatives
Cetuximab
Chemoradiotherapy
Chemotherapy
Colorectal cancer
Colostomy
Cytomegalovirus
Drug therapy
Endoscopy
Esophagitis - chemically induced
Esophagitis - metabolism
Esophagitis - therapy
Esophagoscopy
Fluorouracil - administration & dosage
Gastroenterology
Humans
Internal medicine
Intestinal Obstruction - etiology
Intestinal Obstruction - surgery
Irinotecan
Letter to the Editor
Male
Medical imaging
Medicine
Metastasis
Middle Aged
Molecular Targeted Therapy - adverse effects
Molecular Targeted Therapy - methods
Oncology
Organoplatinum Compounds - administration & dosage
Oxaliplatin
Proctoscopy
Proto-Oncogene Proteins - drug effects
Proto-Oncogene Proteins - genetics
Proto-Oncogene Proteins p21(ras)
ras Proteins - drug effects
ras Proteins - genetics
Rectal Neoplasms - complications
Rectal Neoplasms - diagnosis
Rectal Neoplasms - genetics
Rectal Neoplasms - pathology
Rectal Neoplasms - therapy
Treatment Outcome
Ulcer - chemically induced
Ulcer - metabolism
Ulcer - therapy
Vascular endothelial growth factor
Vascular Endothelial Growth Factor A - drug effects
Vascular Endothelial Growth Factor A - metabolism
Vomiting - etiology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cetuximab, a monoclonal antibody to the extracellular domain of epidermal growth factor receptor (EGFR), is indicated for the treatment of metastatic colorectal cancers and head-neck cancers. Cetuximab is generally well tolerated but some side effects, such as skin rash, malaise, vomiting, diarrhea, hypomagnesemia, and hypersensitivity reactions, have been reported. Esophageal ulcer in patients receiving cetuximab treatment has not been described previously. We herein report a 59-year-old man diagnosed with metastatic rectal cancer with esophageal ulcers associated with cetuximab after five cycles of treatment. To the best of our knowledge, this is the first report that shows cetuximab may induce esophageal ulcers, which may be precursor lesions to a gastrointestinal tract perforation. Citation: Libyan J Med 2014, 9: 23723 - http://dx.doi.org/10.3402/ljm.v9.23723
ISSN:1993-2820
1819-6357
DOI:10.3402/ljm.v9.23723